Marisa Wexler, MS, senior science writer —

Tenax Therapeutics is planning to soon launch a Phase 3 clinical trial of TNX-103, an oral formulation of levosimendan, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The company announced it received clearance from the U.S. Food and Drug Administration (FDA) to conduct…

Beyond Air has been given an innovative technology contract from Vizient for its LungFit PH system, which was approved in the U.S. last year to administer nitric oxide to treat persistent pulmonary hypertension of the newborn (PPHN). “We’re very happy and honored…

Endotronix has been cleared by U.S. regulators to launch a clinical trial testing its Cordella Sensor, an implanted device that measures the pressure in the blood vessels of the lungs, in people with heart failure that slightly limits their physical activity. The study, given the green light by…

The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of sotatercept as a treatment for adults with pulmonary arterial hypertension (PAH). The FDA has given the application priority review, shortening the review time from the usual 10 months to six months. A decision…

Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. Amid ongoing litigation, the U.S. Food and Drug Administration (FDA) has agreed to review an application from Liquidia that seeks to extend the approval of Yutrepia — an inhaled dry powder…

Treatment with VU6047534, an experimental therapy that blocks the activity of a specific type of serotonin receptor, reduced strain on the heart in a mouse model of pulmonary arterial hypertension (PAH) in a new study. The study, “Development of a Peripherally Restricted 5-HT2B Partial Agonist for Treatment…

Treatment with sotatercept in addition to standard pulmonary arterial hypertension (PAH) therapies significantly improved measures of heart health for adults with the disease, according to a new analysis of the STELLAR trial. Results from the Phase 3 trial had already shown the therapy enhanced walking abilities in the participants…

A Phase 3 clinical trial testing high-dose Opsumit (macitentan) in people with chronic thromboembolic pulmonary hypertension (CTEPH) has ended early after an analysis showed the treatment is unlikely to help patients. The announcement was made in a press release from Janssen, the company that markets Opsumit. Opsumit…

The protein LTBP1 is active at high levels in pulmonary arterial hypertension (PAH) and may be a diagnostic marker and therapeutic target in the disease, a new study indicates. “Our study suggests that LTBP1 is involved in the development of PAH and serves as a potential diagnostic and therapeutic…

Psychological counseling and therapy are among the interventions that may help adults with pulmonary hypertension (PH) manage depression and anxiety, a review paper reports. Data in this area are limited, however, and the review highlighted a need for more research into how best to support the mental health…

Tenax Therapeutics has been issued a U.S. patent covering oral levosimendan, also known as TNX-103, for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The patent (U.S. Patent No. 11,701,355) is expected to provide intellectual property protection for TNX-103 through December 2040.

Liquidia has licensed the rights in North America to L606, a novel inhaled formulation of treprostinil that’s being tested in trials of people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). “L606 is the perfect life-cycle complement to our pipeline and…